Specialists in quantifying the current and future burden of non-communicable and rare genetic diseases.
Our data-driven epidemiology generates evidence to support strategic planning and portfolio management at each stage of the drug development process, helping to bring new therapies to patients faster.
From molecule to market, our solutions can help.
Deep expertise in disease epidemiology combined with entrepreneurial vision. Our work has been widely published and peer-reviewed by world-leading experts.
Why Us?We’ve spent over a decade developing our methodology to help you ask the right questions and make the best decisions.
SolutionsWe’ve answered all kinds of questions for many different organisations, covering over 25 NCDs and rare genetic diseases in over 80 countries.
Track RecordOur experienced and multidisciplinary team brings together epidemiologists, geneticists, mathematicians, data scientists, researchers, and software engineers.
About Us
“Prevention, prevention, prevention” – the rallying call from Sandra Gallina, Director General of DG SANTE at the European Commission, set the scene for the core theme that ran through the 10th Politico Health Care Summit in Brussels, on 18th and 19th November. The scale of the challenge The non-communicable disease (NCD) burden across Europe is […]
Read
With the advancement of precision medicine, genetic stratification – dividing patients into subgroups based on their specific mutations – is a key starting point in the drug development lifecycle for rare genetic diseases.
Incorporating a clear stratification plan is a key part of developing an effective Target Product Profile (TPP), which serves as a blueprint for product development by defining what “success” looks like early on, and aligning clinical, regulatory, and commercial strategies to meet patient needs, and regulatory and market requirements.
Read
The Movember Institute of Men’s Health has just released a new report, “The Real Face of Men’s Health”, examining the state of men’s health in Canada,
In 2023, five conditions – coronary heart disease (CHD), colorectal cancer, lung cancer, chronic obstructive pulmonary disease (COPD), and suicide – were responsible for the greatest number of years of life lost to ill health among Canadian men.
HealthLumen was commissioned to carry out the health economic modelling for this report. Our modelling showed that if all preventable cases of these five conditions had been avoided in men in 2023, Canada could have saved $12.4 billion CAD.
Read
In 2024, the World Health Organization (WHO) reported that noncommunicable diseases (NCDs) account for approximately 75% of all deaths worldwide.
For pharmaceutical and biotech companies working in CVRMs, understanding future disease burden is essential to long-term strategy in order to inform decisions regarding where, when and how to invest resources for maximum impact of return. This is important when developing therapeutic interventions, but also for identifying where those interventions can have the greatest impact, and for making the case to act sooner.
In this context, epidemiological modelling is playing a growing role in evidence generation.
Read